Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,606.66
(
0.09%
)
US TECH 100
29,776.40
(
0.22%
)
Dow Jones
51,210.11
(
0.26%
)
Brent Oil
95.40
(
-0.59%
)
Bitcoin
67,441.00
(
-5.50%
)
News Focus
News Focus
Post# of 519088
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

raja48185

Send PM Follow Ignore
Followers 59
Posts 7866
Boards Moderated 0
Alias Born 05/18/2007

raja48185

Re: bas2020 post# 185984

Thursday, 03/21/2019 7:45:53 AM

Thursday, March 21, 2019 7:45:53 AM

Post# of 519088
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease.

All the false assurances when they got together, when the results were no good last time, even as experts openly questioned the intent as Biogen tweaked and twisted the way the trial would be done.!! They are fooling no one.


The vote for Blank Preferred Check offered by AVXL becomes even more important in this context.

ADXS Business Plan for 2019 : Raising more capital

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News